OTCMKTS:ATBPF Antibe Therapeutics (ATBPF) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free ATBPF Stock Alerts $0.22 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.22▼$0.2250-Day Range$0.12▼$0.7852-Week Range$0.11▼$0.89VolumeN/AAverage Volume28,158 shsMarket Capitalization$11.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest Get Antibe Therapeutics alerts: Email Address Ad Whats On FinancePutin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. Click to kickstart your journey to survive in the new economy About Antibe Therapeutics Stock (OTCMKTS:ATBPF)Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Read More ATBPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATBPF Stock News HeadlinesApril 19, 2024 | businesswire.comAntibe Provides Update on CCAA ProceedingsApril 16, 2024 | finance.yahoo.comAntibe Announces TSX Delisting ReviewApril 23, 2024 | Whats On Finance (Ad)Putin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. April 9, 2024 | businesswire.comAntibe Announces Granting of Initial Order Under Companies' Creditors Arrangement ActApril 9, 2024 | businesswire.comAntibe to File an Application for an Initial Order Under Companies' Creditors Arrangement ActApril 1, 2024 | finance.yahoo.comAntibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by NuanceMarch 20, 2024 | businesswire.comAntibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine MeetingMarch 7, 2024 | businesswire.comAntibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine MeetingApril 23, 2024 | Whats On Finance (Ad)Putin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. March 4, 2024 | marketwatch.comAntibe Therapeutics Shares Sink After Arbitration Case LostFebruary 27, 2024 | benzinga.comAntibe Therapeutics Stock (OTC:ATBPF), Insider Trading ActivityFebruary 14, 2024 | finance.yahoo.comAntibe Reports Q3 2024 Interim Financial and Operating ResultsFebruary 14, 2024 | businesswire.comAntibe Reports Q3 2024 Interim Financial and Operating ResultsNovember 13, 2023 | msn.comAntibe Therapeutics reports Q2 resultsNovember 9, 2023 | finance.yahoo.comAntibe Reports PK Results of First Clinical Study of Otenaproxesul’s New FormulationOctober 20, 2023 | finance.yahoo.comIs Antibe Therapeutics (TSE:ATE) In A Good Position To Deliver On Growth Plans?October 18, 2023 | finance.yahoo.comAntibe Initiates First Clinical Study of Otenaproxesul’s New FormulationSeptember 8, 2023 | finance.yahoo.comAntibe Announces Results of 2023 Annual MeetingAugust 14, 2023 | finance.yahoo.comAntibe Reports Q1 2024 Interim Financial and Operating ResultsJune 29, 2023 | finance.yahoo.comAntibe Reports 2023 Year-End Results and Business HighlightsApril 12, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Tuesday (ATE)April 6, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Wednesday (ATE)March 12, 2023 | finance.yahoo.comAntibe Therapeutics Inc. (ATBPF)February 16, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)February 15, 2023 | markets.businessinsider.comEchelon Wealth Partners Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)February 9, 2023 | theglobeandmail.comAntibe Therapeutics: Top 25 Undervalued Dividend Stocks on TSX (ATE)February 7, 2023 | theglobeandmail.comAntibe Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (ATE)See More Headlines Receive ATBPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/23/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ATBPF CUSIPN/A CIKN/A Webwww.antibethera.com Phone(416) 922-3460FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.48% Return on Assets-29.07% Debt Debt-to-Equity RatioN/A Current Ratio10.06 Quick Ratio10.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book0.37Miscellaneous Outstanding Shares53,010,000Free Float48,238,000Market Cap$11.43 million OptionableNot Optionable Beta0.51 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Daniel Marcel Legault J.D. (Age 66)L.L.B., President, CEO, Secretary & Director Comp: $541.96kMr. Alain Wilson M.B.A.MBA, Chief Financial OfficerMr. Scott Curtis C.F.A.M.Eng, Chief Operating OfficerDr. David James Vaughan Ph.D. (Age 74)Chief Development Officer Comp: $295.91kDr. Joseph Stauffer D.O. (Age 58)M.B.A., Chief Medical Officer Comp: $807.8kDr. Ana StegicExecutive Director of Clinical OperationsMs. Christina Cameron B.B.A.Vice President of Investor RelationsMr. Philip SternVice President of CommunicationsMore ExecutivesKey CompetitorsRedHill BiopharmaNASDAQ:RDHLEterna TherapeuticsNASDAQ:ERNAMIRA PharmaceuticalsNASDAQ:MIRANuvo PharmaceuticalsOTCMKTS:MRVFFABVC BioPharmaNASDAQ:ABVCView All Competitors ATBPF Stock Analysis - Frequently Asked Questions Should I buy or sell Antibe Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ATBPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATBPF, but not buy additional shares or sell existing shares. View ATBPF analyst ratings or view top-rated stocks. How have ATBPF shares performed in 2024? Antibe Therapeutics' stock was trading at $0.6820 at the beginning of the year. Since then, ATBPF shares have decreased by 68.4% and is now trading at $0.2156. View the best growth stocks for 2024 here. Are investors shorting Antibe Therapeutics? Antibe Therapeutics saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 3,200 shares, a drop of 64.0% from the March 15th total of 8,900 shares. Based on an average daily trading volume, of 40,600 shares, the short-interest ratio is currently 0.1 days. View Antibe Therapeutics' Short Interest. How were Antibe Therapeutics' earnings last quarter? Antibe Therapeutics Inc. (OTCMKTS:ATBPF) issued its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.03. How do I buy shares of Antibe Therapeutics? Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ATBPF) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
